| Autor: |
Qiu X; National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada., Audet J, Wong G, Fernando L, Bello A, Pillet S, Alimonti JB, Kobinger GP |
| Jazyk: |
angličtina |
| Zdroj: |
Scientific reports [Sci Rep] 2013 Nov 28; Vol. 3, pp. 3365. Date of Electronic Publication: 2013 Nov 28. |
| DOI: |
10.1038/srep03365 |
| Abstrakt: |
Ebola virus (EBOV) is one of the most lethal filoviruses, with mortality rates of up to 90% in humans. Previously, we demonstrated 100% and 50% survival of EBOV-infected cynomologus macaques with a combination of 3 EBOV-GP-specific monoclonal antibodies (ZMAb) administered at 24 or 48 hours post-exposure, respectively. The survivors demonstrated EBOV-GP-specific humoral and cell-mediated immune responses. In order to evaluate whether the immune response induced in NHPs during the ZMAb treatment and EBOV challenge is sufficient to protect survivors against a subsequent exposure, animals that survived the initial challenge were rechallenged at 10 or 13 weeks after the initial challenge. The animals rechallenged at 10 weeks all survived whereas 4 of 6 animals survived a rechallenge at 13 weeks. The data indicate that a robust immune response was generated during the successful treatment of EBOV-infected NHPs with EBOV, which resulted in sustained protection against a second lethal exposure. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
